These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 35932092)

  • 1. Development of virus-like particles-based vaccines against coronaviruses.
    Yong CY; Liew WPP; Ong HK; Poh CL
    Biotechnol Prog; 2022 Nov; 38(6):e3292. PubMed ID: 35932092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.
    Hashemzadeh A; Avan A; Ferns GA; Khazaei M
    Vaccine; 2020 Aug; 38(36):5742-5746. PubMed ID: 32684497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in mRNA and other vaccines against MERS-CoV.
    Tai W; Zhang X; Yang Y; Zhu J; Du L
    Transl Res; 2022 Apr; 242():20-37. PubMed ID: 34801748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies.
    Choi JA; Kim JO
    J Microbiol; 2022 Mar; 60(3):238-246. PubMed ID: 35089585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2.
    Kim C; Kim JD; Seo SU
    J Microbiol; 2022 Mar; 60(3):335-346. PubMed ID: 35089583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
    De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
    Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
    Ye ZW; Jin DY
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2.
    Hemmati F; Hemmati-Dinarvand M; Karimzade M; Rutkowska D; Eskandari MH; Khanizadeh S; Afsharifar A
    Biotechnol Lett; 2022 Jan; 44(1):45-57. PubMed ID: 34837582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
    Nascimento Júnior JAC; Santos AM; Cavalcante RCM; Quintans-Júnior LJ; Walker CIB; Borges LP; Frank LA; Serafini MR
    Drug Dev Ind Pharm; 2021 Apr; 47(4):673-684. PubMed ID: 33826439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically Engineered Live-Attenuated Middle East Respiratory Syndrome Coronavirus Viruses Confer Full Protection against Lethal Infection.
    Gutiérrez-Álvarez J; Honrubia JM; Fernández-Delgado R; Wang L; Castaño-Rodríguez C; Zúñiga S; Sola I; Enjuanes L
    mBio; 2021 Mar; 12(2):. PubMed ID: 33653888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19: Coronavirus Vaccine Development Updates.
    Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
    Front Immunol; 2020; 11():602256. PubMed ID: 33424848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
    Chauhan N; Soni S; Gupta A; Aslam M; Jain U
    J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in virus-like particle-based SARS-CoV-2 vaccines.
    Hao X; Yuan F; Yao X
    Front Cell Infect Microbiol; 2024; 14():1406091. PubMed ID: 38988812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge.
    Park JE; Kim JH; Park JY; Jun SH; Shin HJ
    Virol J; 2022 Jun; 19(1):112. PubMed ID: 35761402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
    Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
    mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells.
    Kato T; Takami Y; Kumar Deo V; Park EY
    J Biotechnol; 2019 Dec; 306():177-184. PubMed ID: 31614169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.